Physician profile
Dyatra B Mitchell
NPI 1285694380
$3,839.73
in general payments reported to CMS, 2019-2025
32 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $411 · 2021: $1,206 · 2022: $659 · 2023: $746 · 2024: $241 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,090.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,089.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $696.42 | 2021-2023 | |
| Pfizer INC. | $472.87 | 2019-2023 | |
| Novo Nordisk INC | $362.68 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $361.52 | 2019-2024 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $291.73 | 2019-2022 | |
| Exact Sciences Corporation | $175.52 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $149.22 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $138.71 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.44 | 2020-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $127.98 | 2020-2023 | Spravato |
| Amgen INC. | $123.27 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $111.70 | 2020-2021 | |
| Radius Health, INC. | $99.73 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.47 | 2021-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $58.58 | 2020-2023 | Trelegy Ellipta |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $56.72 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $53.28 | 2019-2021 | |
| Amarin Pharma, INC. | $45.42 | 2019-2020 | |
| Esperion Therapeutics, INC. | $44.73 | 2023 | Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $44.43 | 2022 | |
| Axsome Therapeutics, INC. | $37.83 | 2023 | Auvelity |
| Inari Medical, INC. | $20.33 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Genentech USA, INC. | $18.51 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.01 | 2023 | Gvoke Hypopen |
| Cranial Technologies, INC | $16.50 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.22 | 2021 | |
| Heartflow, INC. | $16.21 | 2024 | |
| Sanofi-Aventis U.S. LLC | $13.99 | 2020 | |
| Phadia US INC. | $13.86 | 2022 | |
| Allergan, INC. | $12.79 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.79 | 2023 | Quviviq |
| Dexcom, INC. | $12.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dyatra Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.